Additionally, SGLT2 inhibitors have shown promising results in reducing cardiovascular death or HF hospitalisation, as demonstrated in the EMPEROR-preserved study and the DELIVER trial [47,48,49,50,51], especially in patients with mildly reduced or preserved EF, irrespective of their diabetic status. The gene discussed is SLC5A2; the disease is hydrops fetalis.